More Articles

US biosimilar uptake in the light of Obamacare Biosimilars/Research | Posted 05/12/2014

A literature review by researchers at Tufts University in the US concludes that market uptake of biosimilars in the US will depend on regulatory policies, including the smoothing out of issues conc...

Irish pharmacists’ perceptions and attitudes towards generics Generics/Research | Posted 05/12/2014

In June 2013, new legislation came into effect in Ireland - the Health (Pricing and Supply of Medical Goods) Act 2013 - that introduced generics substitution and reference pricing for the first tim...

Biosimilar infliximab launched in Japan Biosimilars/News | Posted 05/12/2014

Japanese pharma firm Nippon Kayaku announced on 28 November 2014 the launch of its infliximab biosimilar, Infliximab BS, in Japan.

Use of biosimilars in rheumatology Biosimilars/Research | Posted 05/12/2014

In order to issue a position statement on the use of biosimilars in rheumatic diseases, the Sociedade Portuguesa de Reumatologia (Portuguese Society of Rheumatology) carried out two systematic...

Cipla makes deal with Serum Institute for vaccines in Europe Pharma News | Posted 05/12/2014

India-based generics maker Cipla announced on 20 November 2014 that it had signed a deal with the Serum Institute of India (Serum Institute) to distribute vaccines in Europe.

Generics makers challenging more patents Reports | Posted 05/12/2014

In recent years generics makers are becoming bolder and challenging more patents on originator drugs. In fact, litigation regarding patents on pharmaceuticals is on the rise, particularly when it c...

Stada to in-license adalimumab biosimilar Biosimilars/News | Posted 05/12/2014

German generics giant Stada Arzneimittel (Stada) announced on 18 November 2014 that it was in negotiations to in-licensing an adalimumab biosimilar.

FDA delays finalization of generics labelling rule Policies & Legislation | Posted 05/12/2014

The US Food and Drug Administration (FDA) is delaying the issue of its controversial rule on generics labelling changes, which was expected to be finalized in December 2014, until autumn 2015.